| Name | Title | Contact Details |
|---|
Lawndale Christian Health Center is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; and HLASeq for human leukocyte antigen and major histocompatibility complex research. In addition, it offers sequence enrichment consumables kits that comprise reagents and consumables, and custom-order libraries; and RainDrop Digital PCR System that transforms the performance of molecular assays by enabling digital answers across various applications, including tumor allele detection, gene expression, copy number variation, and SNP measurement. Further, the company provides remote and onsite response for various emergency repairs, including labor and travel, replacement parts and consumables, software revisions, and preventative maintenance. Its RainStorm technology serves various biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection. The company was founded in 2004 and is headquartered in Lexington, Massachusetts.
Flagship Biosciences is a pathologist-owned digital pathology services CRO that offers quantitative pathology and companion diagnostics development to pharmaceutical and medical device companies, including tissue biomarkers development and multiplexed IHC. Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2010/11/08/prwebprweb4756234.DTL#ixzz15ZpyRlaa
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.